Table 4.
Sensitivity analyses on the risk of VTE in patients with systemic sclerosis
| Outcome | Primary Analysis HR (95% CI) |
Sensitivity Analysis 1 HR (95% CI) |
Sensitivity Analysis 2 HR (95% CI) |
|||
|---|---|---|---|---|---|---|
| Prevalence=10 %a ORb=1.3 |
Prevalence=10 %aORb=3.0 |
Prevalence=20 %aORb=1.3 |
Prevalence=20 %aORb=3.0 |
|||
| PE | 3.73 (1.98, 7.04) | 2.92 (1.45, 5.89) | 3.67 (1.94, 6.92) | 3.22 (1.68, 6.16) | 3.33 (1.75, 6.32) | 2.90 (1.53, 5.52) |
| DVT | 2.96 (1.54, 5.69) | 2.40 (1.15, 5.01) | 2.96 (1.54, 5.70) | 2.85 (1.46, 5.56) | 2.94 (1.52, 5.66) | 2.26 (1.14, 4.46) |
| VTE | 3.47 (2.14, 5.64) | 2.90 (1.71, 4.91) | 3.45 (2.13, 5.59) | 3.11 (1.89, 5.12) | 3.28 (2.02, 5.34) | 2.75 (1.67, 4.52) |
DVT, Deep vein thrombosis; HR, Hazard ratio; OR, Odds ratio; PE, Pulmonary embolism; VTE, Venous thromboembolism
a
hypothetical prevalence of the unmeasured confounder in the SSc cases
b
hypothetical level of association between the unmeasured confounder and the outcome
Sensitivity analyses 1; accounting for the competing risk of death
Sensitivity analyses 2; accounting for unmeasured confounders